{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:43:29Z","timestamp":1790981009922,"version":"4.1.0"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>The objectives of this study were to examine the reasons patients give for nonadherence to allopurinol and to examine differences in intentional nonadherence for patients who did and did not achieve serum urate (SU) levels at treatment target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for \u2265 6 months, completed the Intentional Non-Adherence Scale (INAS). Differences in the types of intentional nonadherence were analyzed between those who did and did not achieve SU at treatment target (&lt; 0.36 mmol\/L, 6 mg\/dL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>The most frequently endorsed reasons for not taking their urate-lowering therapies (ULT) were because participants wanted to lead a normal life (23%) or think of themselves as a healthy person again (20%). Patients also reported not taking allopurinol as a way of testing if they really needed it (22%). Participants with SU above target endorsed significantly more INAS items as reasons for not taking their medication, had more medicine-related concerns, and were more likely to give Testing treatment as a reason for nonadherence. Participants who were younger, single, and non\u2013New Zealand European also endorsed more reasons for not taking their allopurinol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>The major reasons behind the patient\u2019s decision not to take allopurinol relate to the desire to lead a normal life and the strategy of testing the treatment to see if they could reduce the dose without getting symptoms. These results provide some potentially modifiable targets for adherence interventions and some recommendations to clinicians about how to reframe ULT for patients in order to improve adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.210950","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T08:26:20Z","timestamp":1644913580000},"page":"622-626","source":"Crossref","is-referenced-by-count":21,"title":["Why Do Patients With Gout Not Take Allopurinol?"],"prefix":"10.3899","volume":"49","author":[{"given":"Yasaman","family":"Emad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-0166","authenticated-orcid":false,"given":"John","family":"Weinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0775-1045","authenticated-orcid":false,"given":"Trudie","family":"Chalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-2480","authenticated-orcid":false,"given":"Keith J.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"2022062202351348000_49.6.622.1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"American College of Rheumatology Guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022062202351348000_49.6.622.2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.41550","article-title":"Trends in the utilization of urate-lowering therapies following the US Food and Drug Administration\u2019s boxed warning on febuxostat","volume":"73","author":"Kim","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022062202351348000_49.6.622.3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2022062202351348000_49.6.622.4","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.4.437"},{"key":"2022062202351348000_49.6.622.5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22336"},{"key":"2022062202351348000_49.6.622.6","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/key155","article-title":"Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)","volume":"57","author":"Scheepers","year":"2018","journal-title":"Rheumatology"},{"key":"2022062202351348000_49.6.622.7","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S162956"},{"key":"2022062202351348000_49.6.622.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1982.tb00562.x"},{"key":"2022062202351348000_49.6.622.9","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2003.005926"},{"key":"2022062202351348000_49.6.622.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0153-9"},{"key":"2022062202351348000_49.6.622.11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamainternmed.2016.9627","article-title":"Effect of reminder devices on medication adherence: the REMIND randomized clinical trial","volume":"177","author":"Choudhry","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2022062202351348000_49.6.622.12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpsychores.2018.10.010","article-title":"The Intentional Non-Adherence Scale (INAS): initial development and validation","volume":"115","author":"Weinman","year":"2018","journal-title":"J Psychosom Res"},{"key":"2022062202351348000_49.6.622.13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.39799","article-title":"Gout: a roadmap to approaches for improving global outcomes","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022062202351348000_49.6.622.14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/acr.23147","article-title":"Illness perceptions and mortality in patients with gout: a prospective observational study","volume":"69","author":"Serlachius","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022062202351348000_49.6.622.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20570"},{"key":"2022062202351348000_49.6.622.16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/acr2.11095","article-title":"Internalized and anticipated stigmatization in patients with gout","volume":"2","author":"Kleinst\u00e4uber","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2022062202351348000_49.6.622.17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1037\/hea0000548","article-title":"An illness by any other name: the effect of renaming gout on illness and treatment perceptions","volume":"37","author":"Petrie","year":"2018","journal-title":"Health Psychol"},{"key":"2022062202351348000_49.6.622.18","doi-asserted-by":"publisher","DOI":"10.1177\/0963721411429456"},{"key":"2022062202351348000_49.6.622.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8287.2011.02033.x"},{"key":"2022062202351348000_49.6.622.20","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-200207000-00007"},{"key":"2022062202351348000_49.6.622.21","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022062202351348000_49.6.622.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.05.007"},{"key":"2022062202351348000_49.6.622.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140588"},{"key":"2022062202351348000_49.6.622.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017542"},{"key":"2022062202351348000_49.6.622.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32158-5"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T05:37:46Z","timestamp":1655876266000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.3899\/jrheum.210950"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210950","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}